Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TH0318
- Development stage
- Unknown
- Lead developer
- Theratechnologies
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Subcutaneous
01
Overview
TH0318 is an autologous T-cell receptor (TCR) engineered T-cell therapy targeting the Human Endogenous Retrovirus-E (HERV-E) antigen. Developed by T-Cure Bioscience in collaboration with the National Heart, Lung, and Blood Institute (NHLBI), the therapy is designed to treat clear cell renal cell carcinoma (ccRCC). The HERV-E antigen is selectively expressed in ccRCC cells due to the inactivation of the von Hippel-Lindau (VHL) gene, making it a highly specific target with minimal expression in healthy tissues. TH0318 involves the genetic modification of a patient's own T cells to express a TCR that recognizes the HERV-E peptide presented by HLA-A*11:01. The therapy is currently being evaluated in Phase 1 clinical trials for patients with metastatic ccRCC who have failed standard therapies.
- Other names
- HERV-E TCR-TT-Cure HERV-E TCR-T
Beyond the preview
Go deeper on TH0318.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TH0318.